Prevalence of elevated glycated hemoglobin in women with polycystic ovary syndrome

Recently, the American Diabetes Association (ADA) has included glycated hemoglobin A1(c) (A1C) level as a component of diagnostic criteria of odiabetes' or oincreased risk for diabetes'. This study was conducted to examine the prevalence of and risk factors for oelevated A1C' (epsilon 5.7) in women with polycystic ovary syndrome (PCOS). A1C was measured using an immunoturbidimetric assay, and was evaluated in 154 patients with PCOS and 469 age-matched controls (match ratio of 13). All subjects were categorized by BMI (non-obese 25 kg/m(2) and obese epsilon 25 kg/m(2)), and the prevalence of elevated A1C was also analyzed according to BMI. One-third (31.2) of the patients with PCOS had elevated A1C. The prevalence of elevated A1C (epsilon 5.7) was similar in obese women with PCOS and obese controls (23.5 and 20.0, respectively, P 1.0) but non-obese women with PCOS (mean age 29.8 5.3 years) had a higher prevalence of elevated A1C than non-obese controls (31.2 versus 6.6, respectively, P 0.001). Logistic regression analysis of all subjects showed that the odds that a woman has elevated A1C was 6.7 times higher if she has PCOS (adjusted odds ratio 6.67, 95 confidence interval 3.5012.70). The high prevalence of elevated A1C in non-obese patients with PCOS and an increased risk of elevated A1C associated with PCOS suggest that PCOS itself may be associated with abnormal A1C status. Assessing A1C level in young, non-obese patients with PCOS may be a useful new approach to screening for diabetes.